Abstract: The present invention relates to a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. In the formula (1), R1 to R3 are each independently a predetermined amino group or a predetermined amide group, or a group represented by the formula (2), and at least one of R1 to R3 is a group represented by the formula (2).

Abstract: [Problem to be Solved] Provided is a motile cell sorting device that can effectively sort motile cells, such as sperms, having excellent motility and morphology by performing image analysis when animal cells are sorted. [Means for Solution] The motile cell sorting device 1 comprises a storage unit 3, a first introduction unit (cell injection channel) 5, a first introduction control unit 7, a first holding unit (cell capture area) 9, a first derivation unit (cell collection channel) 11, a first derivation control unit 13, a collection unit (liquid storage) 15, a photographing unit 17, and a first controller 19.

Abstract: The present invention provides a pharmaceutical composition containing an inhibitor selected from the group consisting of an EZH1 inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor as an active ingredient, for use in treating HTLV-1-associated myelopathy. The present invention provides a pharmaceutical composition for use in treating HTLV-1-associated myelopathy, containing a 1,3-benzodioxole derivative or a pharmaceutically acceptable salt thereof.

Abstract: The present invention is intended to provide a method for determining the prognosis of a hormone receptor-positive cancer (for example, an ER?-positive breast cancer, an ER?-positive endometrial cancer, etc.) or a method for assisting the determination of the prognosis, and a method for evaluating the sensitivity of the cancer to antihormone therapy or a method for assisting the evaluation of the sensitivity of the cancer to antihormone therapy. Specifically, the present invention relates to a method for determining the prognosis of a hormone receptor-positive cancer, or a method for assisting the determination of the prognosis, which comprises the following steps (a) and (b): (a) a step of detecting Fbxo22-positive cancer cells in a sample derived from the cancer tissues; and (b) a step of calculating the percentage of the Fbxo22-positive cancer cells to the cells present in the sample.

Abstract: An instrument for fixedly transplanting a living body embryo into a uterus has an instrument, for transplanting the living body embryo into the uterus, which is to be inserted into a uterus and a magnetic embryo accommodation container holding instrument (transferred embryo fixing instrument) to be attached to the living body. The instrument for transplanting the living body embryo into the uterus has an embryo accommodation container having an embryo accommodation part having an embryo insertion portion communicating with outside and a magnetic material and a shaft-shaped container transfer tool for separably holding the embryo accommodation container at its distal end portion. The magnetic container holding instrument has an attaching part to be attached to an epidermis of the living body and a magnet capable of attracting the magnetic material of the embryo accommodation container thereto.

Abstract: The present invention provides a therapeutic or prophylactic agent for HTLV-1-associated myelopathy (HAM), comprising an RGMa-inhibiting substance, and a method for treating HTLV-1-associated myelopathy (HAM), comprising administering a pharmacologically effective amount of an RGMa-inhibiting substance to an HAM patient in need thereof.

Abstract: A concentration measurement apparatus measures a temporal relative change amount (?cHb, ?O2Hb) of either or both of total hemoglobin concentration and oxygenated hemoglobin concentration in the head that vary due to repetition of chest compression, and includes a light incidence section making measurement light incident on the head, a light detection section detecting the measurement light propagated through the interior of the head and generating a detection signal in accordance with the intensity of the measurement light, and a CPU determining, based on the detection signal, the relative change amount (?cHb, ?O2Hb) and performing a filtering process of removing frequency components less than a predetermined frequency from frequency components contained in the relative change amount (?cHb, ?O2Hb).

Abstract: A collected living tissue cryopreserving tool is composed of a tissue piece holder and a resin-made accommodating bag. The tissue piece holder is composed of a plate-shaped body part including a thermally conductive plate-shaped lower member and a plate-shaped upper member and a covering sheet held by the plate-shaped body part. The tissue piece holder has a tissue piece placing part formed of a cut-out part provided on the plate-shaped upper member and a part, of an upper surface of the thermally conductive plate-shaped lower member, which is disposed at the cut-out part. The covering sheet is capable of covering the tissue piece placing part.

Abstract: An object of the present invention is to provide a novel therapeutic or preventive agent for human T cell leukemia virus type-1 associated myelopathy (HAM) containing an anti-human CC-chemokine receptor 4 (CCR4) antibody or an antibody fragment thereof as an active ingredient, and characterized by the administration and dosage of the antibody or the antibody fragment thereof. The present invention relates to a therapeutic or preventative agent for HAM characterized in that an anti-human CCR4 antibody or an antibody fragment thereof is contained as an active ingredient and the antibody or the antibody fragment thereof is administered at a low dose.

Abstract: The present invention provides a pharmaceutical composition containing an inhibitor selected from the group consisting of an EZH1 inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor as an active ingredient, for use in treating HTLV-1-associated myelopathy. The present invention provides a pharmaceutical composition for use in treating HTLV-1-associated myelopathy, containing a 1,3-benzodioxole derivative or a pharmaceutically acceptable salt thereof.

Abstract: An instrument for fixedly transplanting a living body embryo into a uterus has an instrument, for transplanting the living body embryo into the uterus, which is to be inserted into a uterus and a magnetic embryo accommodation container holding instrument (transferred embryo fixing instrument) to be attached to the living body. The instrument for transplanting the living body embryo into the uterus has an embryo accommodation container having an embryo accommodation part having an embryo insertion portion communicating with outside and a magnetic material and a shaft-shaped container transfer tool for separably holding the embryo accommodation container at its distal end portion. The magnetic container holding instrument has an attaching part to be attached to an epidermis of the living body and a magnet capable of attracting the magnetic material of the embryo accommodation container thereto.

Abstract: The present invention can provide a controlled drug release carrier formed by using a silk fibroin porous material, which has high drug controlled release rate, controllability of the drug controlled release speed, high strength, easy handleability, skin care properties from high biocompatibility, high water retentivity, and capability of efficiently retaining a drug.

Abstract: The object of the present invention is to provide a new therapeutic method and a new therapeutic agent that are different from known therapeutic medicines for human T cell leukemia virus type-1 (also known as human T lymphotropic virus type-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers. The present invention relates to a therapeutic method and a therapeutic agent for human T cell leukemia virus type-1 (HTLV-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers (ACs), which is characterized by reducing HTLV-1 virus-infected cells using an anti-human CC-chemokine receptor 4 (CCR4) antibody.

Abstract: A concentration measurement apparatus measures a temporal relative change amount (?cHb, ?O2Hb) of either or both of total hemoglobin concentration and oxygenated hemoglobin concentration in the head that vary due to repetition of chest compression, and includes a light incidence section making measurement light incident on the head, a light detection section detecting the measurement light propagated through the interior of the head and generating a detection signal in accordance with the intensity of the measurement light, and a CPU determining, based on the detection signal, the relative change amount (?cHb, ?O2Hb) and performing a filtering process of removing frequency components less than a predetermined frequency from frequency components contained in the relative change amount (?cHb, ?O2Hb).

Abstract: A collected living tissue cryopreserving tool is composed of a tissue piece holder and a resin-made accommodating bag. The tissue piece holder is composed of a plate-shaped body part including a thermally conductive plate-shaped lower member and a plate-shaped upper member and a covering sheet held by the plate-shaped body part. The tissue piece holder has a tissue piece placing part formed of a cut-out part provided on the plate-shaped upper member and a part, of an upper surface of the thermally conductive plate-shaped lower member, which is disposed at the cut-out part. The covering sheet is capable of covering the tissue piece placing part.

Abstract: The object of the present invention is to provide a new therapeutic method and a new therapeutic agent that are different from known therapeutic medicines for human T cell leukemia virus type-1 (also known as human T lymphotropic virus type-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers. The present invention relates to a therapeutic method and a therapeutic agent for human T cell leukemia virus type-1 (HTLV-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers (ACs), which is characterized by reducing HTLV-1 virus-infected cells using an anti-human CC-chemokine receptor 4 (CCR4) antibody.

Abstract: A collected living tissue cryopreserving appliance is composed of a collected tissue accommodating container, a heat-sealable accommodating bag for accommodating the collected tissue accommodating container therein, and a container holding member for holding the collected tissue accommodating container accommodated inside the accommodating bag. The collected tissue accommodating container is composed of a bottomed cylindrical container body and a lid member mountable on the container body in an airtight state. The lid member has a tissue piece placing member and a sealing member, formed on an inner surface of a lid body part, for sealing an open portion of the transparent container body.

Abstract: The object of the present invention is to provide a new therapeutic method and a new therapeutic agent that are different from known therapeutic medicines for human T cell leukemia virus type-1 (also known as human T lymphotropic virus type-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers. The present invention relates to a therapeutic method and a therapeutic agent for human T cell leukemia virus type-1 (HTLV-1) associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers (ACs), which is characterized by reducing HTLV-1 virus-infected cells using an anti-human CC-chemokine receptor 4 (CCR4) antibody.

Abstract: The present invention can provide a controlled drug release carrier formed by using a silk fibroin porous material, which has high drug controlled release rate, controllability of the drug controlled release speed, high strength, easy handleability, skin care properties from high biocompatibility, high water retentivity, and capability of efficiently retaining a drug.

Abstract: A concentration measurement apparatus measures a temporal relative change amount (?cHb, ?O2Hb) of either or both of total hemoglobin concentration and oxygenated hemoglobin concentration in the head that vary due to repetition of chest compression, and includes a light incidence section making measurement light incident on the head, a light detection section detecting the measurement light propagated through the interior of the head and generating a detection signal in accordance with the intensity of the measurement light, and a CPU determining, based on the detection signal, the relative change amount (?cHb, ?O2Hb) and performing a filtering process of removing frequency components less than a predetermined frequency from frequency components contained in the relative change amount (?cHb, ?O2Hb).